Cencora Inc（COR）股票分析CORCencora Inc

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

Cencora Inc appears to be a good buy right now. The current price is $331, which is below several analyst price targets, including $370 from both Baird and Citi. The forward P/E ratio of 15.70 suggests that the stock is reasonably valued compared to its growth potential. Additionally, the recent acquisition of American Oncology Network for $2.4 billion is expected to enhance Cencora's market position in oncology care, which is a positive catalyst for future growth. However, the RSI of 42.25 indicates that the stock is nearing oversold territory, which could present a buying opportunity. The main risk is the recent 5-day change of -2.91%, indicating some short-term volatility.

15 analysts cover COR: 7 rate it Buy, 8 Hold and 0 Sell. The average price target is 415.38.